Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.